To include your compound in the COVID-19 Resource Center, submit it here.

BMY shifting R&D spend, reports earnings

Bristol-Myers (BMY) said on a conference call Monday that it will not grow its R&D budget this year and it will shift a significant portion of its R&D spend to later-stage from discovery programs. A

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers